Benzinga | Dec 14, 2021 07:09AM EST

Evogene Subsidiary Lavie Bio Announces Advancement In Its Bio-Fungicide Program For Fruit Rots

Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), announced today advancement to the pre-commercialization development stage1 in its bio-fungicide program targeting fruit rot diseases. Today's announcement follows the completion of three consecutive years of vineyard trials, including promising 2021 results, conducted in Europe and the U.S., for two of its leading bio-fungicide product candidates, LAV.311 and LAV.312. Lavie Bio has prioritized LAV311 as its lead candidate for final development and submission of a regulatory dossier, expected to be filed with the federal U.S. Environmental Protection Agency (EPA) and California EPA during 2022.